Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation

Eiger Biopharmaceuticals (EIGR) has issued an announcement.

Eiger BioPharmaceuticals, Inc. has filed for Chapter 11 bankruptcy, leading to Nasdaq’s decision to delist the company’s stock due to non-compliance with listing rules. The company won’t appeal the delisting and anticipates its stock to commence trading on the over-the-counter market under the new symbol EIGRQ on April 11, 2024. Additionally, Dr. Jeffrey S. Glenn has resigned from the board, with no disputes influencing his departure.

For detailed information about EIGR stock, go to TipRanks’ Stock Analysis page.